Ignite Creation Date:
2025-12-24 @ 5:29 PM
Ignite Modification Date:
2026-02-27 @ 10:01 AM
Study NCT ID:
NCT04035668
Status:
TERMINATED
Last Update Posted:
2023-01-30
First Post:
2019-07-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Sjögren Syndrome | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | LOU064 | View |
| None | remibrutinib | View |
| None | Sjogren Syndrome | View |
| None | Dry Eye Syndromes | View |
| None | Pathological Processes | View |
| None | Arthritis | View |
| None | Joint Diseases | View |
| None | Musculoskeletal Diseases | View |
| None | Rheumatic Diseases | View |
| None | Xerostomia | View |
| None | Salivary Gland Diseases | View |
| None | Mouth Diseases | View |
| None | Stomatognathic Diseases | View |
| None | Lacrimal Apparatus Diseases | View |
| None | Eye Diseases | View |
| None | Connective Tissue Diseases | View |
| None | Autoimmune Diseases | View |
| None | Immune System Diseases | View |